Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
SAKARNSESakar Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 15 May, 2025 · 12:52 IST

Sakar Healthcare Limited has informed the Exchange regarding Board meeting held on May 15, 2025.

Pat Growth 25pctExceptional ItemRelated Party TransactionsResults View source PDFExplain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.4%Reaction day
₹311.45
prior close
₹317.55
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.0%+1.4% vs market
Pharmaceuticals peers, median of 150sector+0.4%+2.1% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.1
10m
+0.1
15m
+0.9
30m
+0.8
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.4+1.0+1.4+0.4+2.1
Next day
+0.3+1.8-1.4+0.9-0.6
2d
-0.1+3.0-3.1+2.0-2.0
3d
-0.4+1.9-2.3+1.2-1.6
4d
+1.1+2.7-1.6+1.9-0.8
5d
-0.9+2.6-3.4+2.0-2.9
1w
-1.0+3.8-4.9+1.7-2.8
15d
+0.7+5.7-5.0+2.8-2.1
1m
+3.4+6.7-3.3+2.6+0.8
2m
+11.3+9.6+1.7+4.8+6.5
3m
+4.7+4.6+0.1+0.0+4.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sakar Healthcare's board approved its audited FY25 results (standalone and consolidated, both identical figures). Revenue from operations rose about 15.8% to Rs 17,758.47 lakh versus Rs 15,335.17 lakh in FY24. Profit after tax jumped roughly 50% to Rs 1,750.20 lakh (FY24: Rs 1,167.09 lakh), with EPS climbing to Rs 7.97 from Rs 5.64. Q4 FY25 was particularly strong, with PAT of Rs 576.11 lakh (up ~85% year-on-year) on revenue of Rs 5,024.18 lakh. Statutory auditor J.S. Shah & Co. issued an unmodified (clean) opinion, and the company confirmed no deviation in the use of Rs 5.76 crore raised via preferential warrant conversion in December 2024.

Likely market impact

Strong profit growth driven by margin expansion is positive for shareholders; revenue growth is solid but below 20%, while PAT growth well exceeds 25%. Clean audit opinion and no loan defaults support near-term investor confidence.